Intelligent bio solutions completes in-clinic portion of pharmacokinetic (pk) study part of 510(k) pathway for approval & commences review of results

New york, june 28, 2024 (globe newswire) -- intelligent bio solutions inc. (nasdaq: inbs) ("inbs" or the "company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of the in-clinic portion of its pharmacokinetic (pk) study, a core component of the company's clinical study plan for its 510(k) pathway for regulatory approval.
INBS Ratings Summary
INBS Quant Ranking